![(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-acetic acid - chemical structure image](https://media.scbt.com/product/3-4-dihydro-2h-benzob1-4dioxepin-7-yl-acetic-acid-structure_22_96_b_229605.jpg)
![(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-acetic acid - chemical structure image](https://media.scbt.com/product/3-4-dihydro-2h-benzob1-4dioxepin-7-yl-acetic-acid-structure_22_96_t_229605.jpg "Molecular structure of (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-acetic acid")
(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-acetic acid
QUICK LINKS
IBMX is one of the most potent and nonspecific inhibitors of cyclic nucleotide PDE (phosphodiesterases) with documented IC50 values for PDE1, 2, 3, 4, and 5. It is documented to raise intracellular cyclic AMP levels. In rat sensory neurons, the addition of IBMX caused the release of Ca2+ from caffeine ryanodine sensitive internal stores increasing the internal Ca2+ levels and inducing a biphasic membrane current response. Through PDE inhibition, IBMX has also inhibited TNFalpha. IBMX in breast cancer cells has also induced p21 and p27 through a PKA independent pathway. Although a nonspecific PDE inhibitor, IBMX does not show inhibition of PDE8B. In neuroendocrine epithelial cells, IBMX has been observed to inhibit alpha-adrenoceptor-mediated 5-HT release at IC50 = 1.3muM.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-acetic acid, 500 mg | sc-313610 | 500 mg | $285.00 |